Program
Gallium-68
Also written as “[68Ga]Ga-OncoACP3”, “Bombesin (68Ga) labeled (BAY86-7548)” and “[68Ga]Ga DOTA-5G”.
In Novartis's pipeline, Radioligand therapy target HER2
. Its studies are mostly in Prostatic Neoplasms · Breast Neoplasms · Colorectal Neoplasms · Carcinoma, Renal Cell · Urinary Bladder Neoplasms, led by 11 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Philogen | 40 open or running | phase 1since Dec 15, 2022 | Dec 15, 2022 | none ahead |
| Novartis | 31 open or running | phase 3since Jan 26, 2024 | Mar 26, 2018 | Jan 26, 2029phase 1 · NCT07117214 |
| Lantheus | 21 open or running | phase 3since Sep 4, 2026 | Sep 17, 2010 | Sep 30, 2029phase 3 · NCT07831824 |
| Antaros Medical | 11 open or running | early phase 1since Aug 14, 2024 | Aug 14, 2024 | none ahead |
| Bracco | 11 open or running | phase 2since Jun 30, 2026 | Jun 30, 2026 | Feb 2028phase 2 · NCT07702292 |
| GE Healthcare | 11 open or running | phase 3since Oct 9, 2025 | Oct 9, 2025 | Jun 2029phase 3 · NCT07219238 |
| Lumara Bio Oncologics | 11 open or running | phase 2since Dec 21, 2022 | Dec 21, 2022 | Jun 2027phase 2 · NCT05706129 |
| Lumina Pharmaceuticals | 11 open or running | early phase 1since Aug 19, 2026 | Aug 19, 2026 | Sep 1, 2027early phase 1 · NCT07781852 |
| Luminance Biosciences | 11 open or running | phase 1since Oct 29, 2026 | Oct 29, 2026 | Dec 31, 2027phase 1 · NCT07915297 |
| Sanofi | 10 open or running | phase 1since Nov 16, 2017 | Nov 16, 2017 | none ahead |
| SmartNuclide Biopharma | 11 open or running | early phase 1since Oct 10, 2024 | Oct 10, 2024 | none ahead |
Also a collaborator on its studies: medpace-inc and fortrea.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 2 studies since Sep 17, 2010.
- Mar 26, 2018Novartis's first study: phase 2 study in Prostatic NeoplasmsNew to NovartisNovartis · NCT03490032 · 30 enrolled · United States
- Dec 15, 2022Philogen's first study: phase 1 study in Breast NeoplasmsNew to PhilogenPhilogen · NCT05784597 · 18 enrolled · Italy
- Dec 21, 2022Lumara Bio Oncologics's first study: phase 2 study in Carcinoma, Renal CellNew to Lumara Bio OncologicsLumara Bio Oncologics · NCT05706129 · 270 planned · Australia, France
- Jan 26, 2024Phase 3 study in HypersensitivityNovartis · NCT06240741 · 71 enrolled · Japan
- Aug 14, 2024Antaros Medical's first study: early phase 1 study in Crohn DiseaseNew to Antaros MedicalAntaros Medical · NCT06562361 · 30 planned · Sweden
- Oct 10, 2024SmartNuclide Biopharma's first study: early phase 1 study in Adenocarcinoma of the StomachNew to SmartNuclide BiopharmaSmartNuclide Biopharma · NCT06646783 · 28 planned · China
- Feb 17, 20252 phase 1 studiesPhilogen · NCT06840548, NCT06840535
- Jul 22, 2025Phase 1 study in Breast NeoplasmsNovartis · NCT07117214 · 36 planned · Netherlands
- Oct 9, 2025GE Healthcare's first study: phase 3 study in Colorectal NeoplasmsNew to GE HealthcareGE Healthcare · NCT07219238 · 175 planned · United States, Sweden
- May 6, 2026Phase 1 study in Prostatic NeoplasmsPhilogen · NCT07600554 · 20 enrolled · Italy
- Jun 30, 2026Bracco's first study: phase 2 study in Colorectal NeoplasmsNew to BraccoBracco · NCT07702292 · 71 planned · Italy, Netherlands
- Aug 19, 2026Lumina Pharmaceuticals's first study: early phase 1 study in Urinary Bladder NeoplasmsNew to Lumina PharmaceuticalsLumina Pharmaceuticals · NCT07781852 · 40 planned · United States
- Sep 4, 2026Phase 3 study in Prostatic NeoplasmsPhase 3 reachedLantheus · NCT07831824 · 408 planned · United States
- Oct 29, 2026Luminance Biosciences's first study: phase 1 study in Breast NeoplasmsNew to Luminance BiosciencesLuminance Biosciences · NCT07915297 · 10 planned · Australia
Ahead
- Jun 2027Primary completion: phase 2 study in Carcinoma, Renal CellLumara Bio Oncologics · NCT05706129
- Sep 1, 2027Primary completion: early phase 1 study in Urinary Bladder NeoplasmsLumina Pharmaceuticals · NCT07781852
- Dec 31, 2027Primary completion: phase 1 study in Breast NeoplasmsLuminance Biosciences · NCT07915297
- Feb 2028Primary completion: phase 2 study in Colorectal NeoplasmsBracco · NCT07702292
TargetBeta
“Radioligand therapy target HER2”the company's pipeline, read by Claude · source
“Radioligand therapy target FAP”the company's pipeline, read by Claude · source
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Lutetium-177 | Novartis | phase 3 | 24 |
Studies
All 17 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07915297Breast Neoplasms · Australia | 1 | Not yet recruiting | Luminance Biosciences | Dec 31, 2027 | 10 |
| NCT07831824Prostatic Neoplasms · United States | 3 | Recruiting | Lantheus | Sep 30, 2029 | 408 |
| NCT07781852Urinary Bladder Neoplasms · United States | Early 1 | Not yet recruiting | Lumina Pharmaceuticals | Sep 1, 2027 | 40 |
| NCT07702292Colorectal Neoplasms · Italy, Netherlands | 2 | Recruiting | Bracco | Feb 2028 | 71 |
| NCT07600554Prostatic Neoplasms · Italy | 1 | Completed | Philogen | Oct 22, 2026 | 20 |
| NCT07219238Colorectal Neoplasms · United States, Sweden | 3 | Recruiting | GE Healthcare | Jun 2029 | 175 |
| NCT07117214Breast Neoplasms · Netherlands | 1 | Recruiting | Novartis | Jan 26, 2029 | 36 |
| NCT06840548Carcinoma, Renal Cell · Italy | 1 | Completed | Philogen | Nov 28, 2025 | 20 |
| NCT06840535Prostatic Neoplasms · Italy | 1 | Completed | Philogen | Oct 3, 2025 | 20 |
| NCT06646783Adenocarcinoma of the Stomach · China | Early 1 | Not yet recruiting | SmartNuclide Biopharma | Oct 20, 2025 | 28 |
| NCT06562361Crohn Disease · Sweden | Early 1 | Recruiting | Antaros Medical | Dec 2025 | 30 |
| NCT06240741Hypersensitivity · Japan | 3 | Completed | Novartis | Dec 27, 2024 | 71 |
| NCT05706129Carcinoma, Renal Cell · Australia, France | 2 | Recruiting | Lumara Bio Oncologics | Jun 2027 | 270 |
| NCT05784597Breast Neoplasms · Italy | 1 | Completed | Philogen | Oct 21, 2024 | 18 |
| NCT03490032Prostatic Neoplasms · United States | 2 | Completed | Novartis | Aug 20, 2019 | 30 |
| NCT03350191Diabetes Mellitus, Type 2 · Sweden | 1 | Completed | Sanofi | Jun 7, 2018 | 13 |
| NCT01205321Neoplasms · Finland, Germany, Switzerland | 1 | Completed | Lantheus | Nov 2011 | 19 |
How it is read
Names in the registry
- “[68Ga]Ga-OncoACP3”, 2 entries
- “Bombesin (68Ga) labeled (BAY86-7548)”, 2 entries
- “[68Ga]Ga DOTA-5G”, 1 entry
- “[68Ga]-LNTH-2401”, 1 entry
- “[68Ga]BED003”, 1 entry
Conditions, from the studies’ own filings
- Prostatic Neoplasms, 4 studies
- Breast Neoplasms, 3 studies
- Colorectal Neoplasms, 2 studies
- Carcinoma, Renal Cell, 2 studies
- Urinary Bladder Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.